This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Optimer Pharmaceuticals (OPTR)

Q2 2012 Earnings Call

July 31, 2012 5:00 pm ET


David A. Walsey - Vice President of Investor Relations and Corporate Communications

Pedro Lichtinger - Chief Executive Officer, President, Director and Member of New Hire Stock Option Committee

Stephen W. Webster - Chief Financial Officer


Ritu Baral - Canaccord Genuity, Research Division

Brian Skorney - Brean Murray, Carret & Co., LLC, Research Division

Steve Byrne - BofA Merrill Lynch, Research Division

Eun K. Yang - Jefferies & Company, Inc., Research Division

Alan Carr - Needham & Company, LLC, Research Division

Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division

Christopher Holterhoff - Oppenheimer & Co. Inc., Research Division

James F. Molloy - ThinkEquity LLC, Research Division

Juan F. Sanchez - Ladenburg Thalmann & Co. Inc., Research Division

Heather Behanna - JMP Securities LLC, Research Division



Good day, ladies and gentlemen, and welcome to the Optimer Pharmaceuticals Report Second Quarter 2012 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded. I'd like to introduce your host for today's conference, Mr. David Walsey, Optimer Vice President, Investor Relations and Corporate Communications. Mr. Walsey, you may begin.

David A. Walsey

Thank you. Welcome to the Optimer Pharmaceuticals Second Quarter 2012 Conference Call. With me today from the company is our Chief Executive Officer, Pedro Lichtinger and our Chief Financial Officer, Stephen Webster. Please note that this conference call will include forward-looking statements regarding future events and the future financial performance of Optimer, future sales and adoption of DIFICID, including plans and initiatives to facilitate patient access, Optimer's co-promotion agreement, lifecycle management initiatives and commercial efforts, commercialization of DIFICLIR by Astellas Europe, Optimer's plans for additional international commercialization of DIFICID, and future financial results and expenses.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs